Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis. Overall and exposure-adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, John F., Byrd, John C., Ghia, Paolo, Kater, Arnon P., Chanan-Khan, Asher, Furman, Richard R., O’Brien, Susan, Brown, Jennifer R., Munir, Talha, Mato, Anthony, Stilgenbauer, Stephan, Bajwa, Naghmana, Miranda, Paulo, Higgins, Kara, John, Ellie, de Borja, Marianne, Jurczak, Wojciech, Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644206/
https://www.ncbi.nlm.nih.gov/pubmed/37390310
http://dx.doi.org/10.1182/blood.2022018818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644206/
https://www.ncbi.nlm.nih.gov/pubmed/37390310
http://dx.doi.org/10.1182/blood.2022018818

Ejemplares similares